Nordicus Partners Corp. (NORD)
Investor overview
Nordicus Partners is the only publicly traded U.S. business accelerator and holding company focused exclusively on empowering Nordic life sciences companies to succeed in the U.S. market. By combining Nordic scientific innovation with U.S. operational expertise, Nordicus targets transformative, scalable opportunities in high-growth life sciences with unmet medical needs. Current portfolio companies include Orocidin who is developing treatments against aggressive periodontal disease, and Bio-Convert who is focused on preventing oral leukoplakia, a potentially cancerous lesion in the mouth.
Why Invest?
-
Portfolio Diversification Strategy:
Nordicus’ balanced portfolio positions us as a stable and resilient company, mitigating risk with significant upside potential.
-
High-Growth Focus:
Targeting life sciences markets with significant unmet medical needs.
-
Business Strategy:
A clear 4-step process (Scout, Accelerate, Acquire, Exit)
-
Experienced Leadership:
A seasoned team combining Nordic innovation with U.S. market expertise to identify and scale high-potential ventures.
-
Financial Upside:
Portfolio valuations suggest strong potential, leveraging all stock acquisitions to scale effectively.
-
Competitive Edge:
A dual-market approach and expertise in reviving stalled drug candidates, positioning Nordicus uniquely for success.
In The Press
Navigating Corporate Finance in the Life Sciences Sector
Contact
Investor Relations Contact
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel: +1 475 477 9401
Transfer Agent:
Transfer Online, Inc.
512 SE Salmon St.
Portland, OR 97214
Tel:+1 503-227-2950
Mail: info@transferonline.com
Sign up for investor news and email alerts.
Investor
FAQs
Nordicus Partners Corp. resides at 280 S. Beverly Drive, Suite 505, Beverly Hills, CA 90212.
Nordicus Partners Corp. was founded in 1993 under its original Company name; Cardiotech International, Inc.
The whole objective of Nordicus Partners Corp. is to be a publicly traded holding company, providing the right Nordic & U.S. Life Sciences companies with the opportunity and the means of getting established in the U.S.
Nordicus Partners Corp. works as a holding company.
The whole philosophy behind Nordicus Partners Corp. is to eliminate the fees that is usually reserved to investment managers, when you invest in traditional investment vehicles.
The organizational structure at Nordicus Partners Corp. ensures that the entire return accrues to the Nordicus Partners Corp. shareholders, thus maximizing your investment.
The Danish-based management company, Managementselskabet af 12.08.2020 A/S, is a wholly owned subsidiary to Nordicus Partners Corp.
Managementselskabet af 12.08.2020 A/S manages the holding company that is Nordicus Partners Corp.
Nordicus Partners Corp. went public in 1993 under its original name Cardiotech International, Inc. Mitsubishi Chemical Performance Polymers acquired AdvanSource Biomaterials Corporation (formerly Cardiotech International, Inc.) on January 31, 2020, which led to the company becoming a shell company with no operational activity. Conversely, the company changed its name to EKIMAS Corporation and later became Nordicus Partners Corp. as we know it today.
Nordicus Partners Corp. is currently listed on the OTCQB Market, with the ticker symbol "NORD".
Nordicus Partners Corp. fiscal year ends on March 31.
Please contact a stockbroker, bank, or other institution that offers brokerage services to buy or sell Nordicus Partners Corp. common stock.
Please contact our Investor Relations department, using our contact form.
Nordicus Partners Corp. transfer agent is Transfer Online, Inc. They can be reached at the following addresses:
Website: https://transferonline.com/
E-mail inquiries: info@transferonline.com
Transfer Online, Inc.
512 SE Salmon St.
Portland, OR 97214
Please contact our transfer agent, Transfer Online, Inc., to make changes.
Nordicus Partners Corp. will issue a press release announcing each earnings date. In addition, a link to the webcast will also be made available on our website in our “News” section.
Nordicus Partners Corp. does not currently pay dividends.
Nordicus Partners Corp. independent registered public accounting firm is BFBorgers CPA PC.
Our legal counsel is Culhane Meadows Haughian & Walsh PLLC and Shumaker Mallory LLP.
All SEC filings can be accessed directly from the SEC, here.
Nordicus Partners Corp. Investor Relations department can provide information regarding financial performance and business strategy that is already made public.
You can contact Investor Relations through our contact page here.